デフォルト表紙
市場調査レポート
商品コード
1382395

世界の代謝異常治療薬市場:考察と予測 (2029年まで)

Global Drugs for Treating Metabolic Disorders Market Insights, Forecast to 2029

出版日: | 発行: QYResearch | ページ情報: 英文 92 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.09円
世界の代謝異常治療薬市場:考察と予測 (2029年まで)
出版日: 2023年11月20日
発行: QYResearch
ページ情報: 英文 92 Pages
納期: 2~3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、代謝異常治療薬 (Drugs for Treating Metabolic Disorders) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 代謝異常治療薬の製品概要
  • 市場:タイプ別
    • 世界の代謝異常治療薬の市場規模成長率:タイプ別, 2018 VS 2022 VS 2029
    • Antidiabetic Drugs
    • Antihypertensive Drugs
    • Hypolipidemic Drugs
    • Others
  • 市場:用途別
    • 世界の代謝異常治療薬の市場規模成長率:用途別, 2018 VS 2022 VS 2029
    • Hospital
    • Pharmacy
  • 前提条件と制限
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の代謝異常治療薬売上予測・予想 2018-2029
  • 世界の代謝異常治療薬の収益:地域別
    • 世界の代謝異常治療薬の収益:地域別: 2018 VS 2022 VS 2029
    • 世界の代謝異常治療薬の収益:地域別 (2018-2023)
    • 世界の代謝異常治療薬の収益:地域別 (2024-2029)
    • 世界の代謝異常治療薬の収益市場シェア 地域別 (2018-2029)
  • 世界の代謝異常治療薬売上予測・予想 2018-2029
  • 世界の代謝異常治療薬の販売:地域別
    • 世界の代謝異常治療薬の販売:地域別: 2018 VS 2022 VS 2029
    • 世界の代謝異常治療薬の販売:地域別 (2018-2023)
    • 世界の代謝異常治療薬の販売:地域別 (2024-2029)
    • 世界の代謝異常治療薬の販売市場シェア 地域別 (2018-2029)
  • 米国・カナダ
  • 欧州
  • 中国
  • アジア(中国を除く)
  • 中東, アフリカ ・ラテンアメリカ

第3章 競合:企業別

  • 世界の代謝異常治療薬の販売:企業別
    • 世界の代謝異常治療薬の販売:企業別 (2018-2023)
    • 世界の代謝異常治療薬の販売市場シェア:企業別 (2018-2023)
    • 世界の上位10・上位5企業: 代謝異常治療薬 in 2022
  • 世界の代謝異常治療薬の収益:企業別
    • 世界の代謝異常治療薬の収益:企業別 (2018-2023)
    • 世界の代謝異常治療薬の収益市場シェア:企業別 (2018-2023)
    • 世界の上位10・上位5企業: 代謝異常治療薬の収益 2022
  • 世界の主要企業 代謝異常治療薬, 業界ランキング, 2021 VS 2022 VS 2023
  • 世界の代謝異常治療薬の販売価格:企業別
  • 競合情勢の分析
    • 企業の市場集中度 (CR5 and HHI)
    • 世界の代謝異常治療薬の市場シェア:企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 世界の主要メーカー 代謝異常治療薬, 製造拠点分布と本社
  • 世界の主要メーカー 代謝異常治療薬, 提供製品と用途
  • 世界の主要メーカー 代謝異常治療薬, 業界参入時期
  • M&A, 拡張計画

第4章 市場規模:タイプ別

  • 世界の代謝異常治療薬の販売:タイプ別
    • 世界の代謝異常治療薬の販売実績:タイプ別 (2018-2023)
    • 世界の代謝異常治療薬の販売予測:タイプ別 (2024-2029)
    • 世界の代謝異常治療薬の販売市場シェア:タイプ別 (2018-2029)
  • 世界の代謝異常治療薬 収益:タイプ別
    • 世界の代謝異常治療薬の収益実績:タイプ別 (2018-2023)
    • 世界の代謝異常治療薬の収益予測:タイプ別 (2024-2029)
    • 世界の代謝異常治療薬の収益市場シェア:タイプ別 (2018-2029)
  • 世界の代謝異常治療薬の価格:タイプ別
    • 世界の代謝異常治療薬の価格:タイプ別 (2018-2023)
    • 世界の代謝異常治療薬の価格予測:タイプ別 (2024-2029)

第5章 市場規模:用途別

  • 世界の代謝異常治療薬の販売:用途別
    • 世界の代謝異常治療薬の販売実績:用途別 (2018-2023)
    • 世界の代謝異常治療薬の販売予測:用途別 (2024-2029)
    • 世界の代謝異常治療薬の販売市場シェア:用途別 (2018-2029)
  • 世界の代謝異常治療薬の収益:用途別
    • 世界の代謝異常治療薬の収益実績:用途別 (2018-2023)
    • 世界の代謝異常治療薬の収益予測:用途別 (2024-2029)
    • 世界の代謝異常治療薬の収益市場シェア:用途別 (2018-2029)
  • 世界の代謝異常治療薬の価格:用途別
    • 世界の代謝異常治療薬の価格:用途別 (2018-2023)
    • 世界の代謝異常治療薬の価格予測:用途別 (2024-2029)

第6章 米国・カナダ

  • 米国・カナダ 代謝異常治療薬 市場規模:タイプ別
    • 米国・カナダ 代謝異常治療薬の販売:タイプ別 (2018-2029)
    • 米国・カナダ 代謝異常治療薬 収益:タイプ別 (2018-2029)
  • 米国・カナダ 代謝異常治療薬 市場規模:用途別
    • 米国・カナダ 代謝異常治療薬の販売:用途別 (2018-2029)
    • 米国・カナダ 代謝異常治療薬の収益:用途別 (2018-2029)
  • 米国・カナダ 代謝異常治療薬 市場規模:国別
    • 米国・カナダ 代謝異常治療薬の収益:国別: 2018 VS 2022 VS 2029
    • 米国・カナダ 代謝異常治療薬の販売:国別 (2018-2029)
    • 米国・カナダ 代謝異常治療薬の収益:国別 (2018-2029)
    • US
    • カナダ

第7章 欧州

  • 欧州の代謝異常治療薬 市場規模:タイプ別
    • 欧州の代謝異常治療薬の販売:タイプ別 (2018-2029)
    • 欧州の代謝異常治療薬 収益:タイプ別 (2018-2029)
  • 欧州の代謝異常治療薬 市場規模:用途別
    • 欧州の代謝異常治療薬の販売:用途別 (2018-2029)
    • 欧州の代謝異常治療薬の収益:用途別 (2018-2029)
  • 欧州の代謝異常治療薬 市場規模:国別
    • 欧州の代謝異常治療薬の収益:国別: 2018 VS 2022 VS 2029
    • 欧州の代謝異常治療薬の販売:国別 (2018-2029)
    • 欧州の代謝異常治療薬の収益:国別 (2018-2029)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 中国

  • 中国の代謝異常治療薬 市場規模
    • 中国の代謝異常治療薬 売上 (2018-2029)
    • 中国の代謝異常治療薬 収益 (2018-2029)
  • 中国の代謝異常治療薬 市場規模:用途別
    • 中国の代謝異常治療薬の販売:用途別 (2018-2029)
    • 中国の代謝異常治療薬の収益:用途別 (2018-2029)

第9章 アジア(中国を除く)

  • アジア地域 代謝異常治療薬 市場規模:タイプ別
    • アジア地域 代謝異常治療薬の販売:タイプ別 (2018-2029)
    • アジア地域 代謝異常治療薬 収益:タイプ別 (2018-2029)
  • アジア地域 代謝異常治療薬 市場規模:用途別
    • アジア地域 代謝異常治療薬の販売:用途別 (2018-2029)
    • アジア地域 代謝異常治療薬の収益:用途別 (2018-2029)
  • アジア地域 代謝異常治療薬の販売:地域別
    • アジア地域 代謝異常治療薬の収益:地域別: 2018 VS 2022 VS 2029
    • アジア地域 代謝異常治療薬の収益:地域別 (2018-2029)
    • アジア地域 代謝異常治療薬の販売:地域別 (2018-2029)
    • 日本
    • 韓国
    • 台湾
    • 東南アジア
    • インド

第10章 中東, アフリカ ・ラテンアメリカ

  • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬 市場規模:タイプ別
    • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬の販売:タイプ別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬 収益:タイプ別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬 市場規模:用途別
    • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬の販売:用途別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬の収益:用途別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬の販売:国別
    • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬の収益:国別: 2018 VS 2022 VS 2029
    • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬の収益:国別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの代謝異常治療薬の販売:国別 (2018-2029)
    • ブラジル
    • メキシコ
    • トルコ
    • イスラエル
    • 湾岸協力理事会諸国

第11章 企業プロファイル

  • Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • AstraZeneca
  • Merck
  • Johnson & Johnson
  • Boehringer Ingelheim
  • Gilead Sciences

第12章 業界チェーンと販売チャネルの分析

  • 代謝異常治療薬 業界チェーン分析
  • 代謝異常治療薬 主要原材料
    • 主要原材料
    • 原材料の主要サプライヤー
  • 代謝異常治療薬 生産形態とプロセス
  • 代謝異常治療薬 販売およびマーケティング
    • 代謝異常治療薬 販売チャネルs
    • 代謝異常治療薬 卸業者
  • 代謝異常治療薬 顧客

第13章 市場動向

  • 代謝異常治療薬 業界動向
  • 代謝異常治療薬 市場の促進要因
  • 代謝異常治療薬 市場の課題
  • 代謝異常治療薬 市場の抑制要因

第14章 主な調査結果 世界の代謝異常治療薬の主な市場調査結果

第15章 付録

図表

List of Tables

  • Table 1. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 2. Major Manufacturers of Antidiabetic Drugs
  • Table 3. Major Manufacturers of Antihypertensive Drugs
  • Table 4. Major Manufacturers of Hypolipidemic Drugs
  • Table 5. Major Manufacturers of Others
  • Table 6. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 7. Global Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 8. Global Drugs for Treating Metabolic Disorders Revenue by Region (2018-2023) & (US$ Million)
  • Table 9. Global Drugs for Treating Metabolic Disorders Revenue by Region (2024-2029) & (US$ Million)
  • Table 10. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2018-2023)
  • Table 11. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2024-2029)
  • Table 12. Global Drugs for Treating Metabolic Disorders Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 13. Global Drugs for Treating Metabolic Disorders Sales by Region (2018-2023) & (K Units)
  • Table 14. Global Drugs for Treating Metabolic Disorders Sales by Region (2024-2029) & (K Units)
  • Table 15. Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2018-2023)
  • Table 16. Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2024-2029)
  • Table 17. Global Drugs for Treating Metabolic Disorders Sales by Manufacturers (2018-2023) & (K Units)
  • Table 18. Global Drugs for Treating Metabolic Disorders Sales Share by Manufacturers (2018-2023)
  • Table 19. Global Drugs for Treating Metabolic Disorders Revenue by Manufacturers (2018-2023) & (US$ Million)
  • Table 20. Global Drugs for Treating Metabolic Disorders Revenue Share by Manufacturers (2018-2023)
  • Table 21. Global Key Players of Drugs for Treating Metabolic Disorders, Industry Ranking, 2021 VS 2022 VS 2023
  • Table 22. Drugs for Treating Metabolic Disorders Price by Manufacturers 2018-2023 (US$/Unit)
  • Table 23. Global Drugs for Treating Metabolic Disorders Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 24. Global Drugs for Treating Metabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Treating Metabolic Disorders as of 2022)
  • Table 25. Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Manufacturing Base Distribution and Headquarters
  • Table 26. Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Product Offered and Application
  • Table 27. Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Date of Enter into This Industry
  • Table 28. Mergers & Acquisitions, Expansion Plans
  • Table 29. Global Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
  • Table 30. Global Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
  • Table 31. Global Drugs for Treating Metabolic Disorders Sales Share by Type (2018-2023)
  • Table 32. Global Drugs for Treating Metabolic Disorders Sales Share by Type (2024-2029)
  • Table 33. Global Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
  • Table 34. Global Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
  • Table 35. Global Drugs for Treating Metabolic Disorders Revenue Share by Type (2018-2023)
  • Table 36. Global Drugs for Treating Metabolic Disorders Revenue Share by Type (2024-2029)
  • Table 37. Drugs for Treating Metabolic Disorders Price by Type (2018-2023) & (US$/Unit)
  • Table 38. Global Drugs for Treating Metabolic Disorders Price Forecast by Type (2024-2029) & (US$/Unit)
  • Table 39. Global Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
  • Table 40. Global Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
  • Table 41. Global Drugs for Treating Metabolic Disorders Sales Share by Application (2018-2023)
  • Table 42. Global Drugs for Treating Metabolic Disorders Sales Share by Application (2024-2029)
  • Table 43. Global Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
  • Table 44. Global Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
  • Table 45. Global Drugs for Treating Metabolic Disorders Revenue Share by Application (2018-2023)
  • Table 46. Global Drugs for Treating Metabolic Disorders Revenue Share by Application (2024-2029)
  • Table 47. Drugs for Treating Metabolic Disorders Price by Application (2018-2023) & (US$/Unit)
  • Table 48. Global Drugs for Treating Metabolic Disorders Price Forecast by Application (2024-2029) & (US$/Unit)
  • Table 49. US & Canada Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
  • Table 50. US & Canada Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
  • Table 51. US & Canada Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
  • Table 52. US & Canada Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
  • Table 53. US & Canada Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
  • Table 54. US & Canada Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
  • Table 55. US & Canada Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
  • Table 56. US & Canada Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
  • Table 57. US & Canada Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 58. US & Canada Drugs for Treating Metabolic Disorders Revenue by Country (2018-2023) & (US$ Million)
  • Table 59. US & Canada Drugs for Treating Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
  • Table 60. US & Canada Drugs for Treating Metabolic Disorders Sales by Country (2018-2023) & (K Units)
  • Table 61. US & Canada Drugs for Treating Metabolic Disorders Sales by Country (2024-2029) & (K Units)
  • Table 62. Europe Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
  • Table 63. Europe Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
  • Table 64. Europe Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
  • Table 65. Europe Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
  • Table 66. Europe Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
  • Table 67. Europe Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
  • Table 68. Europe Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
  • Table 69. Europe Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
  • Table 70. Europe Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 71. Europe Drugs for Treating Metabolic Disorders Revenue by Country (2018-2023) & (US$ Million)
  • Table 72. Europe Drugs for Treating Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
  • Table 73. Europe Drugs for Treating Metabolic Disorders Sales by Country (2018-2023) & (K Units)
  • Table 74. Europe Drugs for Treating Metabolic Disorders Sales by Country (2024-2029) & (K Units)
  • Table 75. China Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
  • Table 76. China Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
  • Table 77. China Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
  • Table 78. China Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
  • Table 79. China Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
  • Table 80. China Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
  • Table 81. China Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
  • Table 82. China Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
  • Table 83. Asia Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
  • Table 84. Asia Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
  • Table 85. Asia Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
  • Table 86. Asia Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
  • Table 87. Asia Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
  • Table 88. Asia Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
  • Table 89. Asia Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
  • Table 90. Asia Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
  • Table 91. Asia Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 92. Asia Drugs for Treating Metabolic Disorders Revenue by Region (2018-2023) & (US$ Million)
  • Table 93. Asia Drugs for Treating Metabolic Disorders Revenue by Region (2024-2029) & (US$ Million)
  • Table 94. Asia Drugs for Treating Metabolic Disorders Sales by Region (2018-2023) & (K Units)
  • Table 95. Asia Drugs for Treating Metabolic Disorders Sales by Region (2024-2029) & (K Units)
  • Table 96. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Type (2018-2023) & (K Units)
  • Table 97. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Type (2024-2029) & (K Units)
  • Table 98. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Type (2018-2023) & (US$ Million)
  • Table 99. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Type (2024-2029) & (US$ Million)
  • Table 100. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Application (2018-2023) & (K Units)
  • Table 101. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Application (2024-2029) & (K Units)
  • Table 102. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Application (2018-2023) & (US$ Million)
  • Table 103. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Application (2024-2029) & (US$ Million)
  • Table 104. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 105. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country (2018-2023) & (US$ Million)
  • Table 106. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
  • Table 107. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country (2018-2023) & (K Units)
  • Table 108. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country (2024-2029) & (K Units)
  • Table 109. Novo Nordisk Company Information
  • Table 110. Novo Nordisk Description and Major Businesses
  • Table 111. Novo Nordisk Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 112. Novo Nordisk Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 113. Novo Nordisk Recent Developments
  • Table 114. Sanofi Company Information
  • Table 115. Sanofi Description and Major Businesses
  • Table 116. Sanofi Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 117. Sanofi Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 118. Sanofi Recent Developments
  • Table 119. Eli Lilly and Company Company Information
  • Table 120. Eli Lilly and Company Description and Major Businesses
  • Table 121. Eli Lilly and Company Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 122. Eli Lilly and Company Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 123. Eli Lilly and Company Recent Developments
  • Table 124. AstraZeneca Company Information
  • Table 125. AstraZeneca Description and Major Businesses
  • Table 126. AstraZeneca Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 127. AstraZeneca Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 128. AstraZeneca Recent Developments
  • Table 129. Merck Company Information
  • Table 130. Merck Description and Major Businesses
  • Table 131. Merck Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 132. Merck Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 133. Merck Recent Developments
  • Table 134. Johnson & Johnson Company Information
  • Table 135. Johnson & Johnson Description and Major Businesses
  • Table 136. Johnson & Johnson Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 137. Johnson & Johnson Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 138. Johnson & Johnson Recent Developments
  • Table 139. Boehringer Ingelheim Company Information
  • Table 140. Boehringer Ingelheim Description and Major Businesses
  • Table 141. Boehringer Ingelheim Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 142. Boehringer Ingelheim Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 143. Boehringer Ingelheim Recent Developments
  • Table 144. Gilead Sciences Company Information
  • Table 145. Gilead Sciences Description and Major Businesses
  • Table 146. Gilead Sciences Drugs for Treating Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 147. Gilead Sciences Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 148. Gilead Sciences Recent Developments
  • Table 149. Key Raw Materials Lists
  • Table 150. Raw Materials Key Suppliers Lists
  • Table 151. Drugs for Treating Metabolic Disorders Distributors List
  • Table 152. Drugs for Treating Metabolic Disorders Customers List
  • Table 153. Drugs for Treating Metabolic Disorders Market Trends
  • Table 154. Drugs for Treating Metabolic Disorders Market Drivers
  • Table 155. Drugs for Treating Metabolic Disorders Market Challenges
  • Table 156. Drugs for Treating Metabolic Disorders Market Restraints
  • Table 157. Research Programs/Design for This Report
  • Table 158. Key Data Information from Secondary Sources
  • Table 159. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Drugs for Treating Metabolic Disorders Product Picture
  • Figure 2. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 3. Global Drugs for Treating Metabolic Disorders Market Share by Type in 2022 & 2029
  • Figure 4. Antidiabetic Drugs Product Picture
  • Figure 5. Antihypertensive Drugs Product Picture
  • Figure 6. Hypolipidemic Drugs Product Picture
  • Figure 7. Others Product Picture
  • Figure 8. Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 9. Global Drugs for Treating Metabolic Disorders Market Share by Application in 2022 & 2029
  • Figure 10. Hospital
  • Figure 11. Pharmacy
  • Figure 12. Drugs for Treating Metabolic Disorders Report Years Considered
  • Figure 13. Global Drugs for Treating Metabolic Disorders Revenue, (US$ Million), 2018 VS 2022 VS 2029
  • Figure 14. Global Drugs for Treating Metabolic Disorders Revenue 2018-2029 (US$ Million)
  • Figure 15. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region in Percentage: 2022 Versus 2029
  • Figure 16. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2018-2029)
  • Figure 17. Global Drugs for Treating Metabolic Disorders Sales 2018-2029 ((K Units)
  • Figure 18. Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2018-2029)
  • Figure 19. US & Canada Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
  • Figure 20. US & Canada Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
  • Figure 21. Europe Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
  • Figure 22. Europe Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
  • Figure 23. China Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
  • Figure 24. China Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
  • Figure 25. Asia (excluding China) Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
  • Figure 26. Asia (excluding China) Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
  • Figure 27. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales YoY (2018-2029) & (K Units)
  • Figure 28. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue YoY (2018-2029) & (US$ Million)
  • Figure 29. The Drugs for Treating Metabolic Disorders Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
  • Figure 30. The Top 5 and 10 Largest Manufacturers of Drugs for Treating Metabolic Disorders in the World: Market Share by Drugs for Treating Metabolic Disorders Revenue in 2022
  • Figure 31. Global Drugs for Treating Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
  • Figure 32. Global Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
  • Figure 33. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
  • Figure 34. Global Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
  • Figure 35. Global Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
  • Figure 36. US & Canada Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
  • Figure 37. US & Canada Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
  • Figure 38. US & Canada Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
  • Figure 39. US & Canada Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
  • Figure 40. US & Canada Drugs for Treating Metabolic Disorders Revenue Share by Country (2018-2029)
  • Figure 41. US & Canada Drugs for Treating Metabolic Disorders Sales Share by Country (2018-2029)
  • Figure 42. U.S. Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 43. Canada Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 44. Europe Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
  • Figure 45. Europe Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
  • Figure 46. Europe Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
  • Figure 47. Europe Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
  • Figure 48. Europe Drugs for Treating Metabolic Disorders Revenue Share by Country (2018-2029)
  • Figure 49. Europe Drugs for Treating Metabolic Disorders Sales Share by Country (2018-2029)
  • Figure 50. Germany Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 51. France Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 52. U.K. Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 53. Italy Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 54. Russia Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 55. China Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
  • Figure 56. China Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
  • Figure 57. China Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
  • Figure 58. China Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
  • Figure 59. Asia Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
  • Figure 60. Asia Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
  • Figure 61. Asia Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
  • Figure 62. Asia Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
  • Figure 63. Asia Drugs for Treating Metabolic Disorders Revenue Share by Region (2018-2029)
  • Figure 64. Asia Drugs for Treating Metabolic Disorders Sales Share by Region (2018-2029)
  • Figure 65. Japan Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 66. South Korea Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 67. China Taiwan Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 68. Southeast Asia Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 69. India Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 70. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
  • Figure 71. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
  • Figure 72. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
  • Figure 73. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
  • Figure 74. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue Share by Country (2018-2029)
  • Figure 75. Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales Share by Country (2018-2029)
  • Figure 76. Brazil Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 77. Mexico Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 78. Turkey Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 79. Israel Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 80. GCC Countries Drugs for Treating Metabolic Disorders Revenue (2018-2029) & (US$ Million)
  • Figure 81. Drugs for Treating Metabolic Disorders Value Chain
  • Figure 82. Drugs for Treating Metabolic Disorders Production Process
  • Figure 83. Channels of Distribution
  • Figure 84. Distributors Profiles
  • Figure 85. Bottom-up and Top-down Approaches for This Report
  • Figure 86. Data Triangulation
  • Figure 87. Key Executives Interviewed
目次

This research report focuses on the Drugs for Treating Metabolic Disorders Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Drugs for Treating Metabolic Disorders Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
    • 1.2.2 Antidiabetic Drugs
    • 1.2.3 Antihypertensive Drugs
    • 1.2.4 Hypolipidemic Drugs
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Drugs for Treating Metabolic Disorders Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
    • 1.3.2 Hospital
    • 1.3.3 Pharmacy
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Executive Summary

  • 2.1 Global Drugs for Treating Metabolic Disorders Sales Estimates and Forecasts 2018-2029
  • 2.2 Global Drugs for Treating Metabolic Disorders Revenue by Region
    • 2.2.1 Global Drugs for Treating Metabolic Disorders Revenue by Region: 2018 VS 2022 VS 2029
    • 2.2.2 Global Drugs for Treating Metabolic Disorders Revenue by Region (2018-2023)
    • 2.2.3 Global Drugs for Treating Metabolic Disorders Revenue by Region (2024-2029)
    • 2.2.4 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Region (2018-2029)
  • 2.3 Global Drugs for Treating Metabolic Disorders Sales Estimates and Forecasts 2018-2029
  • 2.4 Global Drugs for Treating Metabolic Disorders Sales by Region
    • 2.4.1 Global Drugs for Treating Metabolic Disorders Sales by Region: 2018 VS 2022 VS 2029
    • 2.4.2 Global Drugs for Treating Metabolic Disorders Sales by Region (2018-2023)
    • 2.4.3 Global Drugs for Treating Metabolic Disorders Sales by Region (2024-2029)
    • 2.4.4 Global Drugs for Treating Metabolic Disorders Sales Market Share by Region (2018-2029)
  • 2.5 US & Canada
  • 2.6 Europe
  • 2.7 China
  • 2.8 Asia (excluding China)
  • 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

  • 3.1 Global Drugs for Treating Metabolic Disorders Sales by Manufacturers
    • 3.1.1 Global Drugs for Treating Metabolic Disorders Sales by Manufacturers (2018-2023)
    • 3.1.2 Global Drugs for Treating Metabolic Disorders Sales Market Share by Manufacturers (2018-2023)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Drugs for Treating Metabolic Disorders in 2022
  • 3.2 Global Drugs for Treating Metabolic Disorders Revenue by Manufacturers
    • 3.2.1 Global Drugs for Treating Metabolic Disorders Revenue by Manufacturers (2018-2023)
    • 3.2.2 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Manufacturers (2018-2023)
    • 3.2.3 Global Top 10 and Top 5 Companies by Drugs for Treating Metabolic Disorders Revenue in 2022
  • 3.3 Global Key Players of Drugs for Treating Metabolic Disorders, Industry Ranking, 2021 VS 2022 VS 2023
  • 3.4 Global Drugs for Treating Metabolic Disorders Sales Price by Manufacturers
  • 3.5 Analysis of Competitive Landscape
    • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.5.2 Global Drugs for Treating Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.6 Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Manufacturing Base Distribution and Headquarters
  • 3.7 Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Product Offered and Application
  • 3.8 Global Key Manufacturers of Drugs for Treating Metabolic Disorders, Date of Enter into This Industry
  • 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Drugs for Treating Metabolic Disorders Sales by Type
    • 4.1.1 Global Drugs for Treating Metabolic Disorders Historical Sales by Type (2018-2023)
    • 4.1.2 Global Drugs for Treating Metabolic Disorders Forecasted Sales by Type (2024-2029)
    • 4.1.3 Global Drugs for Treating Metabolic Disorders Sales Market Share by Type (2018-2029)
  • 4.2 Global Drugs for Treating Metabolic Disorders Revenue by Type
    • 4.2.1 Global Drugs for Treating Metabolic Disorders Historical Revenue by Type (2018-2023)
    • 4.2.2 Global Drugs for Treating Metabolic Disorders Forecasted Revenue by Type (2024-2029)
    • 4.2.3 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Type (2018-2029)
  • 4.3 Global Drugs for Treating Metabolic Disorders Price by Type
    • 4.3.1 Global Drugs for Treating Metabolic Disorders Price by Type (2018-2023)
    • 4.3.2 Global Drugs for Treating Metabolic Disorders Price Forecast by Type (2024-2029)

5 Market Size by Application

  • 5.1 Global Drugs for Treating Metabolic Disorders Sales by Application
    • 5.1.1 Global Drugs for Treating Metabolic Disorders Historical Sales by Application (2018-2023)
    • 5.1.2 Global Drugs for Treating Metabolic Disorders Forecasted Sales by Application (2024-2029)
    • 5.1.3 Global Drugs for Treating Metabolic Disorders Sales Market Share by Application (2018-2029)
  • 5.2 Global Drugs for Treating Metabolic Disorders Revenue by Application
    • 5.2.1 Global Drugs for Treating Metabolic Disorders Historical Revenue by Application (2018-2023)
    • 5.2.2 Global Drugs for Treating Metabolic Disorders Forecasted Revenue by Application (2024-2029)
    • 5.2.3 Global Drugs for Treating Metabolic Disorders Revenue Market Share by Application (2018-2029)
  • 5.3 Global Drugs for Treating Metabolic Disorders Price by Application
    • 5.3.1 Global Drugs for Treating Metabolic Disorders Price by Application (2018-2023)
    • 5.3.2 Global Drugs for Treating Metabolic Disorders Price Forecast by Application (2024-2029)

6 US & Canada

  • 6.1 US & Canada Drugs for Treating Metabolic Disorders Market Size by Type
    • 6.1.1 US & Canada Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
    • 6.1.2 US & Canada Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
  • 6.2 US & Canada Drugs for Treating Metabolic Disorders Market Size by Application
    • 6.2.1 US & Canada Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
    • 6.2.2 US & Canada Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
  • 6.3 US & Canada Drugs for Treating Metabolic Disorders Market Size by Country
    • 6.3.1 US & Canada Drugs for Treating Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029
    • 6.3.2 US & Canada Drugs for Treating Metabolic Disorders Sales by Country (2018-2029)
    • 6.3.3 US & Canada Drugs for Treating Metabolic Disorders Revenue by Country (2018-2029)
    • 6.3.4 US
    • 6.3.5 Canada

7 Europe

  • 7.1 Europe Drugs for Treating Metabolic Disorders Market Size by Type
    • 7.1.1 Europe Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
    • 7.1.2 Europe Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
  • 7.2 Europe Drugs for Treating Metabolic Disorders Market Size by Application
    • 7.2.1 Europe Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
    • 7.2.2 Europe Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
  • 7.3 Europe Drugs for Treating Metabolic Disorders Market Size by Country
    • 7.3.1 Europe Drugs for Treating Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029
    • 7.3.2 Europe Drugs for Treating Metabolic Disorders Sales by Country (2018-2029)
    • 7.3.3 Europe Drugs for Treating Metabolic Disorders Revenue by Country (2018-2029)
    • 7.3.4 Germany
    • 7.3.5 France
    • 7.3.6 U.K.
    • 7.3.7 Italy
    • 7.3.8 Russia

8 China

  • 8.1 China Drugs for Treating Metabolic Disorders Market Size
    • 8.1.1 China Drugs for Treating Metabolic Disorders Sales (2018-2029)
    • 8.1.2 China Drugs for Treating Metabolic Disorders Revenue (2018-2029)
  • 8.2 China Drugs for Treating Metabolic Disorders Market Size by Application
    • 8.2.1 China Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
    • 8.2.2 China Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)

9 Asia (excluding China)

  • 9.1 Asia Drugs for Treating Metabolic Disorders Market Size by Type
    • 9.1.1 Asia Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
    • 9.1.2 Asia Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
  • 9.2 Asia Drugs for Treating Metabolic Disorders Market Size by Application
    • 9.2.1 Asia Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
    • 9.2.2 Asia Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
  • 9.3 Asia Drugs for Treating Metabolic Disorders Sales by Region
    • 9.3.1 Asia Drugs for Treating Metabolic Disorders Revenue by Region: 2018 VS 2022 VS 2029
    • 9.3.2 Asia Drugs for Treating Metabolic Disorders Revenue by Region (2018-2029)
    • 9.3.3 Asia Drugs for Treating Metabolic Disorders Sales by Region (2018-2029)
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 China Taiwan
    • 9.3.7 Southeast Asia
    • 9.3.8 India

10 Middle East, Africa and Latin America

  • 10.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Market Size by Type
    • 10.1.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Type (2018-2029)
    • 10.1.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Type (2018-2029)
  • 10.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Market Size by Application
    • 10.2.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Application (2018-2029)
    • 10.2.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Application (2018-2029)
  • 10.3 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country
    • 10.3.1 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029
    • 10.3.2 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Revenue by Country (2018-2029)
    • 10.3.3 Middle East, Africa and Latin America Drugs for Treating Metabolic Disorders Sales by Country (2018-2029)
    • 10.3.4 Brazil
    • 10.3.5 Mexico
    • 10.3.6 Turkey
    • 10.3.7 Israel
    • 10.3.8 GCC Countries

11 Company Profiles

  • 11.1 Novo Nordisk
    • 11.1.1 Novo Nordisk Company Information
    • 11.1.2 Novo Nordisk Overview
    • 11.1.3 Novo Nordisk Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.1.4 Novo Nordisk Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Novo Nordisk Recent Developments
  • 11.2 Sanofi
    • 11.2.1 Sanofi Company Information
    • 11.2.2 Sanofi Overview
    • 11.2.3 Sanofi Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.2.4 Sanofi Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Sanofi Recent Developments
  • 11.3 Eli Lilly and Company
    • 11.3.1 Eli Lilly and Company Company Information
    • 11.3.2 Eli Lilly and Company Overview
    • 11.3.3 Eli Lilly and Company Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.3.4 Eli Lilly and Company Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Eli Lilly and Company Recent Developments
  • 11.4 AstraZeneca
    • 11.4.1 AstraZeneca Company Information
    • 11.4.2 AstraZeneca Overview
    • 11.4.3 AstraZeneca Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.4.4 AstraZeneca Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 AstraZeneca Recent Developments
  • 11.5 Merck
    • 11.5.1 Merck Company Information
    • 11.5.2 Merck Overview
    • 11.5.3 Merck Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.5.4 Merck Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Merck Recent Developments
  • 11.6 Johnson & Johnson
    • 11.6.1 Johnson & Johnson Company Information
    • 11.6.2 Johnson & Johnson Overview
    • 11.6.3 Johnson & Johnson Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.6.4 Johnson & Johnson Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Johnson & Johnson Recent Developments
  • 11.7 Boehringer Ingelheim
    • 11.7.1 Boehringer Ingelheim Company Information
    • 11.7.2 Boehringer Ingelheim Overview
    • 11.7.3 Boehringer Ingelheim Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.7.4 Boehringer Ingelheim Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Boehringer Ingelheim Recent Developments
  • 11.8 Gilead Sciences
    • 11.8.1 Gilead Sciences Company Information
    • 11.8.2 Gilead Sciences Overview
    • 11.8.3 Gilead Sciences Drugs for Treating Metabolic Disorders Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.8.4 Gilead Sciences Drugs for Treating Metabolic Disorders Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 Gilead Sciences Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Drugs for Treating Metabolic Disorders Industry Chain Analysis
  • 12.2 Drugs for Treating Metabolic Disorders Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Drugs for Treating Metabolic Disorders Production Mode & Process
  • 12.4 Drugs for Treating Metabolic Disorders Sales and Marketing
    • 12.4.1 Drugs for Treating Metabolic Disorders Sales Channels
    • 12.4.2 Drugs for Treating Metabolic Disorders Distributors
  • 12.5 Drugs for Treating Metabolic Disorders Customers

13 Market Dynamics

  • 13.1 Drugs for Treating Metabolic Disorders Industry Trends
  • 13.2 Drugs for Treating Metabolic Disorders Market Drivers
  • 13.3 Drugs for Treating Metabolic Disorders Market Challenges
  • 13.4 Drugs for Treating Metabolic Disorders Market Restraints

14 Key Findings in The Global Drugs for Treating Metabolic Disorders Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer